Conrad Fischer highlights zilebesiran as a long-acting RNA interference therapy that can lower blood pressure for up to 24 weeks after a single injection, pointing to a potential shift toward infrequent dosing for hypertension.
Clinical trials have demonstrated that zilebesiran provides dose-dependent and sustained blood pressure reductions lasting up to 24 weeks after a single subcutaneous injection
Zilebesiran
*Long-acting RNA interference (RNAi)
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare